The Kyphon Assist™ Directional Cannula allows physicians greater control when inflating the bone tamp while also increasing height restoration capability compared to a traditional balloon kyphoplasty cannula
During the current COVID-19 pandemic, procedures, and therapies that reduce exposure to other people are important because that also reduces the potential for spreading the virus. The results were presented at the annual Heart Rhythm Society Scientific Sessions, held virtually for the first time.
Medtronic Onyx ONE Clear Study met its primary endpoint of cardiac death or myocardial infarction by beating a performance goal derived from contemporary one-month DAPT trials at one-year post-procedure.
The study showed low rates of all-cause mortality or stroke at 30 days (1.3%) with a low rate of serious procedural complications, and no annular rupture or aortic dissection.
It has already launched its new Respiratory Infectious Disease Health Check to existing MCMS customers, and it is now launching a new COVID-19 Virtual Care Evaluation and Monitoring solution available to U.S. health systems, health plans and employers.
Medtronic reports PFA uses pulsed electric fields to ablate or create lesions and scar tissue to interrupt irregular electrical pathways in the heart and the triggers of aFib.
Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart (the atria and the ventricle) are impaired.
The availability of the new technologies on January 15 will expand access to sacral neuromodulation (SNM) therapy for thousands of potential European patients by offering full-body MRI scan eligible, lifestyle-friendly choices with either the InterStim Micro or InterStim II neurostimulators.
4/17/19: Two-Year Endosuture Aneurysm Repair (ESAR) Data: Medtronic shared preliminary two-year data supporting the safety, durability, and effectiveness of Endurant to treat AAA patients with short aortic necks when used in combination with the Heli-FX(TM) EndoAnchor(TM) system.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.